Protocol digest of a randomized controlled Phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced oesophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomy: Japan Clinical Oncology Group study JCOG2206 (SUNRISE Trial)
Authors:
- Ryosuke KitaRKRyosuke Kita
- Satoru MatsudaSMSatoru Matsuda
- Motoo NomuraMNMotoo Nomura
- Ryunosuke MachidaRMRyunosuke Machida
- Keita SasakiKSKeita Sasaki
- Ken KatoKKKen Kato
- Rei GotoRGRei Goto
- Takashi YoshiokaTYTakashi Yoshioka
- Shun YamamotoSYShun Yamamoto
- Takahiro TsushimaTTTakahiro Tsushima
- Haruhiko FukudaHFHaruhiko Fukuda
- Hiroya TakeuchiHTHiroya Takeuchi
Open Access
- 26 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (2) , 212-216
Abstract
Although the efficacy of postoperative therapy with nivolumab after preoperative chemoradiotherapy for locally advanced oesophageal cancer has been proven in Western countries, the survival benefits of postoperative therapy after preoperative chemotherapy with docetaxel, cisplatin and 5-FU or cisplatin plus 5-FU as the Japanese standard therapy remain controversial. This randomized Phase III trial was designed to confirm the superiority of postoperative therapy with nivolumab over observation alone and S-1 over observation alone in patients with locally advanced oesophageal squamous cell carcinoma with no pathological complete response after preoperative chemotherapy followed by curative esophagectomy. A total of 450 patients will be enrolled from 56 hospitals in Japan over 5.5 years. The primary endpoint is relapse-free survival, and the secondary endpoints are disease-free survival, overall survival, adverse events and incremental cost-effectiveness ratio. This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031230219 (https://jrct.niph.go.jp/latest-detail/jRCTs031230219).Keywords
Funding Information
- National Cancer Center Research and Development Funds (2023-J-03)
This publication has 13 references indexed in Scilit:
- Phase II trial of perioperative chemotherapy of esophageal cancer: PIECE trial.Journal of Clinical Oncology, 2022
- A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.Journal of Clinical Oncology, 2022
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerNew England Journal of Medicine, 2021
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2019
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialThe Lancet Oncology, 2015
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- Applying Bayesian ideas in drug development and clinical trialsStatistics in Medicine, 1993
- Discrete sequential boundaries for clinical trialsBiometrika, 1983
- An aid to data monitoring in long-term clinical trialsControlled Clinical Trials, 1982
- Nomograms for Calculating the Number of Patients Needed for a Clinical Trial with Survival as an Endpoint1982